Financing - August 6, 2014
Novo Nordisk shares going steadily up
Danish Novo Nordisk shares are rising steadily this year, zooming past British competitor GlaxoSmithKline. Bloomberg recently reported that the company’s shares have gone up by 27 percent during 2014 with a total market cap of $120 billion, passing GSK by several billions which according to stock exchange experts comes as quite a surprise. Its 2014 sales forecast amounts to […]
Financing - July 3, 2014
Vaccibody completes NOK 35 million financing
Norwegian company Vaccibody has through a new share issue completed a NOK 35 million financing. The financing comes from both existing and new investors. The largest new investor is represented by Datum and partners, which will take a seat in the Board of Directors. Arctic Securities is the manager for the share issue. According to Vaccibody, […]
Financing - June 27, 2014
Xvivo completes private placement of shares
The board of directors of Xvivo Perfusion AB has resolved to issue 1,950,000 new shares in Xvivo through a private placement directed to a group of qualified Swedish and international investors. The subscription price for each new share was set to SEK 37.50 through a book-building procedure. Through the Private Placement Xvivo raises SEK 73,125,000 before issue costs. The […]
Financing - June 26, 2014
Novo Nordisk to double revenue says deputy CEO
Danish drugmaker Novo Nordisk expects to double its annual revenue within the next ten years, according to deputy CEO Kåre Schultz. Novo Nordisk has had a tough year so far as the company failed to post double-digit sales growth in the first quarter for the first time in four years. But the results for 2014 might be a […]
Financing - June 12, 2014
Targovax completes 70 MNOK financing
Immunotherapy specialist Targovax has completed a 70 MNOK financing, mainly from new investors. CEO Hanne M Kristensen states; “The capital increase of 70 MNOK will make us able to continue developing Targovax’s pipeline of immunotherapies targeting RAS mutated cancer forms, and also gives us a strong position to develop Targovax as a company”. Chairman Jónas Einarsson […]
Financing - May 28, 2014
Moberg Pharma completes share issue of SEK 60 million
The company has completed a directed share issue of 2.1 million new shares, which brings SEK 60 million to the company before transaction costs. The new share issue, which was resolved by the Board of the company on May 27th, 2014 with authorization from the Annual General Meeting on May 13th, 2014, includes 2,068,965 new […]
